Literature DB >> 12954114

Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells.

Petar Lenert1, Ae-Kyung Yi, Arthur M Krieg, Laura L Stunz, Robert F Ashman.   

Abstract

The proliferative response of primary B cells to CpG oligonucleotides (ODN) involves induction of nuclear activation promoting-1 (AP-1) transcription factor. AP-1 subunits c-Fos, Fos-B, Jun-B, and Jun-D, but not Fra-1 or Fra-2, were all induced by CpG ODNs in B cells within 30 minutes of stimulation, followed by c-Jun at 1-2 hours. c-Jun reached maximum at 6 hours. By 40 hours, Jun-B and Jun-D became dominant. Synthetic ODNs containing a single guanosine triplet/tetrad appropriately distanced from the 5' pyrimidine-rich unit, which inhibit CpG-driven cell cycle entry and apoptosis protection, blocked AP-1 induction by stimulatory ODNs when they were added simultaneously. After 30 minutes of stimulation, adding inhibitor no longer affected AP-1 at 6 hours. No AP-1 subunits escaped ODN inhibition. In a cell line transfected with an AP-1-beta-galactosidase reporter construct, CpG ODN-induced AP-1 transcriptional activity was prevented by inhibitory ODN, but lipopolysaccharide (LPS)-induced AP-1 activity was not. These data suggest that inhibitory ODNs block the CpG ODN-driven signaling pathway at a site proximal to AP-1 induction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954114     DOI: 10.1089/108729003768247600

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  13 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

3.  Characterization of immunostimulatory CpG-rich sequences from different Bifidobacterium species.

Authors:  Odile Ménard; Valérie Gafa; Nathalie Kapel; Bertrand Rodriguez; Marie-José Butel; Anne-Judith Waligora-Dupriet
Journal:  Appl Environ Microbiol       Date:  2010-03-05       Impact factor: 4.792

4.  Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Authors:  Robert F Ashman; J Adam Goeken; Petar S Lenert
Journal:  Int Immunopharmacol       Date:  2011-03-02       Impact factor: 4.932

5.  Endosomal Toll-Like Receptors Mediate Enhancement of Interleukin-17A Production Triggered by Epstein-Barr Virus DNA in Mice.

Authors:  Marwa Shehab; Nour Sherri; Hadi Hussein; Noor Salloum; Elias A Rahal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 6.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

Review 7.  Structural requirements and applications of inhibitory oligodeoxyribonucleotides.

Authors:  Robert F Ashman; Petar Lenert
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

8.  Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity.

Authors:  Mirjam Peter; Konrad Bode; Grayson B Lipford; Florian Eberle; Klaus Heeg; Alexander H Dalpke
Journal:  Immunology       Date:  2007-10-23       Impact factor: 7.397

9.  TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation.

Authors:  Tony J Vanden Bush; Gail A Bishop
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.